The paper's citation list

No.
The paper's citation list
1
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments. 2025;14: doi: 10.3389/fonc.2024.1514120
2
Long noncoding RNAs as therapeutic targets to overcome chemoresistance in ovarian cancer. 2022;10: doi: 10.3389/fcell.2022.999174
3
Combined radiomics-clinical model to predict platinum-sensitivity in advanced high-grade serous ovarian carcinoma using multimodal MRI. 2024;14: doi: 10.3389/fonc.2024.1341228
4
Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?. 2023;16: doi: 10.1186/s13048-023-01259-2
5
The first-in-class pro-apoptotic peptide PEP-010 is effective in monotherapy and in combination with paclitaxel on resistant ovarian adenocarcinoma cell models. 2024;15: doi: 10.3389/fphar.2024.1444973
6
Ovarian tumor microenvironment contributes to tumor progression and chemoresistance. 2024; doi: 10.20517/cdr.2024.111
7
Production of novel peptide‐targeting antibodies for anti‐Müllerian hormone receptor 2 and induction of cytotoxicity in ovarian cancer cells. 2025;101: doi: 10.1111/sji.13426
8
Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer. 2023;14: doi: 10.3389/fimmu.2023.1204148
9
Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen. 2025;91:220 doi: 10.1111/bcp.16250
10
Nafamostat mesylate sensitizes ovarian cancer cells to carboplatin by promoting the ZNF24-mediated inhibition of WNT2B. 2024;49:467 doi: 10.2131/jts.49.467
11
Therapeutic Chemoresistance in Ovarian Cancer: Emerging Hallmarks, Signaling Mechanisms and Alternative Pathways. 2025;32:923 doi: 10.2174/0109298673276871231205043417
12
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models. 2024;42:644 doi: 10.1007/s10637-024-01479-3
13
Exosomal miR-4516 derived from ovarian cancer stem cells enhanced cisplatin tolerance in ovarian cancer by inhibiting GAS7. 2024;927:148738 doi: 10.1016/j.gene.2024.148738
14
Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma. 2023;13: doi: 10.3389/fonc.2023.1252700
15
Multiaction Pt(IV) Complexes: Cytotoxicity in Ovarian Cancer Cell Lines and Mechanistic Studies. 2024;63:14958 doi: 10.1021/acs.inorgchem.4c01586
16
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite. 2024;90:568 doi: 10.1111/bcp.15937
17
Editorial: Molecular influences in therapies in ovarian cancer. 2022;12: doi: 10.3389/fonc.2022.991769
18
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives. 2024;24:649 doi: 10.1080/14737140.2024.2362178
19
Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers. 2025;13: doi: 10.3389/fcell.2025.1485422
20
Emerging role of m6A modification in ovarian cancer: progression, drug resistance, and therapeutic prospects. 2024;14: doi: 10.3389/fonc.2024.1366223
21
Cell and Molecular Biology of Ovarian Cancer. 2024;1452:1 doi: 10.1007/978-3-031-58311-7_1
22
Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors. 2024; doi: 10.20517/cdr.2023.152
23
Circular RNAs in gynecologic cancers: mechanisms and implications for chemotherapy resistance. 2023;14: doi: 10.3389/fphar.2023.1194719
24
The role of macrophage polarization in ovarian cancer: from molecular mechanism to therapeutic potentials. 2025;16: doi: 10.3389/fimmu.2025.1543096
25
Effects of Arborvitae (Thuja plicata) Essential Oil on Cervical Cancer Cells: Insights into Molecular Mechanisms. 2024;24:1483 doi: 10.2174/0118715206308864240823095507
26
Selected phenotypic and functional changes in ovarian cancer cells treated in vitro with combined therapy using cisplatin and hyperthermia. 2023;77:115 doi: 10.18794/aams/159291
27
Multicompartmentalized Microvascularized Tumor-on-a-Chip to Study Tumor-Stroma Interactions and Drug Resistance in Ovarian Cancer. 2024;17:345 doi: 10.1007/s12195-024-00817-y
Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/